SHMT1 Polymorphism in Parkinson's Disease,

May 30, 2021 updated by: Effat AETony, MD, Assiut University

Genetic Polymorphisms of Serine Hydroxylmethyl Transferase 1 (SHMT1) in Patients With Parkinson's Disease

Parkinson Disease (PD) is the most common movement disorder and represents the second most common degenerative disease of the central nervous system . SHMT has been shown to be associated with various diseases.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This case -control observational prospective study will conducted on 40 patients with PD.

Study Type

Observational

Enrollment (Anticipated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

patient with parkinson diisease

Description

Inclusion Criteria:

  • Patients age ≥ 50 years.
  • Patients with PD diagnosed according to the United Kingdom Parkinson's Disease Society Brain Bank (UK PDS Brain Bank diagnostic criteria)

Exclusion Criteria:

  • Patients with parkinsonian plus syndrome

    • Patients with secondary parkinsonism
    • Patients with other chronic comorbidities (renal, hepatic, and endocrinal disturbances and chronic chest disease.)
    • Past and /or present history of epilepsy.
    • Patients with disturbed conscious level.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
GROUP 1
Group 1 (patients with PD) All participants will be subjected to thorough history taking, full clinical and neurological examination. Diagnosis of PD by using Brain Bank Criteria for diagnosis of Parkinson Disease , assessment of the severity of PD by using PDRS and evaluation of cognitive functions using MMSE.
Genetic: SHMT1 polymorphism
It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.
Group 2
Group 2 (controls) All participants will be subjected to thorough history taking, full clinical and neurological examination.
Genetic: SHMT1 polymorphism
It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
polymorphism of SHMT1gene
Time Frame: one year
one year

Secondary Outcome Measures

Outcome Measure
Time Frame
the role of SHMT1plymorphism in pathogenesis PD
Time Frame: one year
one year
Study the relationship of Shmt1 polymorphism to the severity of Parkinson disease
Time Frame: One year
One year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Collaborators

Aswan University Hospital

Investigators

  • Principal Investigator: Abeer a tony, MD, Assistant Professor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 31, 2021

Primary Completion (Anticipated)

July 1, 2021

Study Completion (Anticipated)

January 1, 2022

Study Registration Dates

First Submitted

January 3, 2021

First Submitted That Met QC Criteria

January 9, 2021

First Posted (Actual)

January 12, 2021

Study Record Updates

Last Update Posted (Actual)

June 2, 2021

Last Update Submitted That Met QC Criteria

May 30, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • aswan

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Study the Role of SHMT1 Polymorphism in Parkinson Disease

Clinical Trials on SHMT1 polymorphism

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe